bluuebunny/crossref_metadata_2025_split huggingface dataset:
MO644: Comparative Analysis of Survival and Morbidity in Home and Hospital Haemodialysis
Authors: Todorov Sakic Verica , Djuric Petar , Jankovic Aleksandar , Bulatovic Ana , Bjedov Jelena , Djuric Zivka , Pešić Snezana , Dimkovic Nada , Naumovic Radomir 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Many studies have shown that home haemodialysis (HOHD) provides fewer complications and better outcomes as compared with hospital haemodialysis (HHD). The aim of this study was to compare morbidity and survival in patients on HOHD and HHD.

METHOD
We analysed 26 prevalent HOHD patients who were matched with 52 HHD patients according to sex, age and Davies Comorbidity Index (DCI). DCI is based on seven groups of comorbidities: ischaemic heart disease (IHD), left ventricular dysfunction (LVD), peripheral vascular disease (PVD), malignancy, diabetes mellitus (DM), systemic collagen vascular disease and other significant pathology. Grade 0 had patients without any of these comorbidities, grade 1 those with 1–2 and those with 3 or more comorbidities had grade 2. Patients were followed from January 2011 to January 2020. We analysed an overall number of hospitalizations during the study period, a number of hospitalizations per year (annual hospital admission rate) and longevity of in-hospital stay (days). We categorized each hospitalization into 1 of 4 causes: cardiovascular disease (CVD), infection, vascular access dysfunction, or other cause.

RESULTS
Median age for HOHD and HHD patients was 55.7 and 56 years respectively and 77% of patients in both groups were men. Majority of the patients in both groups had DCI 1 (65%), 31% had DCI 0 and only 4% had DCI 2. The most common comorbidity for both HOHD and HHD patients was IHD (35% and 29% respectively), followed by HCV infection (35% and 17% respectively) and PVD (11.5% and 15% respectively). There was no difference between HOHD and HHD patients in an overall number of hospitalization (3.7 ± 3.3 versus 3.9 ± 2.8; P = .47), nor in annual admission rate for all-cause morbidity (0.5 ± 0.4 versus 0.6 ± 0.4; P = .28), but HHD patients had longer in-hospital stay (7.4 ± 9.8 days versus 9.3 ± 8.7 days; P = .05). Cause-specific morbidity showed that HHD patients had a more frequent annual admission rate for CVD (0.2 ± 0.1 versus 0.4 ± 0.3; P = .05), while there were no differences for infections (0.3 ± 0.2 versus 0.3 ± 0.3; P = .9) nor vascular access complications (0.3 ± 0.3 versus 0.4 ± 0.3; P = .3). Also, annual in-hospital stays for CVD (3.0 ± 3.1 versus 4.0 ± 4.5 days; P = .5), infection (6.4 ± 7.5 versus 5.7 ± 7.6 days; P = .6) and vascular access complications (6.0 ± 7.0 versus 7.7 ± 7.8 days; P = .5) did not differ between HOHD and HHD group. Kaplan–Meier curve revealed that survival in HOHD and HHD patients were 92.3% versus 90.4% at 3 years, 84.6% versus 70.2% at 5 years and 55.7% versus 50% at 9 years (log-rank test P = .5).

CONCLUSION
Our study has shown that HOHD and HHD patients had similar hospitalization rates, but patients on HOHD had better rehabilitation and shorter hospitalizations for all-cause morbidity. Despite this, HHD and HOHD patients had similar survival rates.
MO654: Automatic KUF Max Determination as a Tool to Prescribe a Personalized Convection Flow in Post-Dilution Haemodiafiltration by Predicting the Transmembrane Pressure to Which the System will be Subjected
Authors: Ficheux Alain , Laget Jonas , Duranton Flore , Gayrard Nathalie , Vetromille Fernando , Szwarc Ilan , Servel Marie-Françoise , Argiles Ciscart Angel 
Published: May 2022

Abstract

BACKGROUND AND AIM
Post-dilutional haemodiafiltration (HDF) with high convection volumes are suggested to improve survival. However, a large increase in convection flow (QUF) is associated with high transmembrane pressure (TMP) which, when exceeding limits advised by guidelines, acts as a limiting factor and prevents achieving the prescription. Our aim is to predict the TMP needed to reach any given convection flow for a patient and dialysis session.

METHOD
The TMP necessary to obtain a desired convection was predicted from the automatic determination of the maximum ultrafiltration coefficient (KUF max, HDF machine Dialog iQ, BBraun, Melsungen, Germany) and compared to the actual value for 16 patients and 29 dialysis sessions. KUF max was determined at the start of the session and the coefficients of the quadratic regression of the ultrafiltration coefficient (KUF) on convection flow (KUF = a*(QUF)² + b* QUF + c) were obtained and used to predict the TMP needed to obtain a convection of 30% of QB (QUF max), knowing that TMP = QUF/KUF. Then, infusion rate was set at QUF max and the observed TMP was recorded after 8 minutes stabilization. Dialyses were performed with the patient's usual dialyzer (Diacap pro for 28 sessions, Nephral 400 for 1 session) and blood flow [363 ± 30 mL/min (300–400 mL/min)]. Observed and estimated TMPs were compared.

RESULTS
There was a high correlation between both TMPs (Pearson's R = 0.98; P &lt; .01). The Bland and Altman analysis showed an average difference (systematic bias) of 3.3% with 95% limits of agreement of −9 and +15% and a maximal difference of 12%, indicating a slight overestimation.

CONCLUSION
KUF max determination allows estimating TMP at any QUF prescription with an acceptable error (3%). Therefore, the KUF on QUF parabolic curve may be of help in the clinical setting to prescribe the most suitable convection in post-dilutional HDF by predicting the TMP the filtrating system will be submitted to. Based on this principle, automatic systems to aid personalized convection flow prescriptions can be developed.
MO658: Effect of a Time-Dependent Dialysate Bicarbonate Concentration on Intradialytic and Postdialytic Blood Bicarbonate Kinetics
Authors: Wieliczko Monika , Twardowska-Kawalec Malgorzata , Debowska Malgorzata , Mauro Pietribiasi , Waniewski Jacek , (Ken) Leypoldt John , Malyszko Jolanta 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Use of a high dialysate bicarbonate (HCO3) concentration during haemodialysis (HD) is associated with higher patient mortality, potentially due to post-dialytic metabolic alkalosis [1]; it remains unclear how to optimize dialysate HCO3 concentration ([HCO3]) to both neutralize interdialytic acid generation and minimize post-dialytic alkalosis. We compared the effects of an intradialytic increasing or decreasing dialysate [HCO3] during HD on blood bicarbonate kinetics.

METHOD
Blood [HCO3] was measured in 11 chronic, thrice-weekly HD patients (5 male, 6 female) during 4-h treatments with i) constant dialysate [HCO3] of 35 mEq/L; ii) dialysate [HCO3] of 35 mEq/L for the first 2-h and 30 mEq/L for the second 2-h; and iii) dialysate [HCO3] of 30 mEq/L for the first 2-h and 35 mEq/L for the second 2-h. Treatment interventions were fixed during a given week, and arterial blood samples were obtained at the start of treatment, every hour during the treatment and 1-h after the treatment during the second and third treatments of the week; a total of 66 HD treatments were monitored. Blood acid-base composition was determined using a blood gas analyzer; [HCO3] was calculated from measured pH and partial pressure of carbon dioxide using the Henderson–Hasselbalch equation. Blood [HCO3] for each patient was averaged over the second and third treatment of the week. HCO3 transfer from dialysate to blood was calculated by numerical integration of the time-dependence of the blood bicarbonate profile assuming a constant dialyzer dialysate of 198 mL/min. Blood flow rates were 250–350 mL/min and were relatively constant for each patient; dialysate flow rates were always 500 mL/min.

RESULTS
Pre- and post-dialytic body weights were 71.1 ± 12.6 kg and 69.5 ± 12.1 kg [mean ± standard deviation (SD)], respectively, during the first study treatment. Mean values of blood [HCO3] are shown in the Figure; certain statistics are tabulated.
Blood pH at the start of treatment was not different (P = 0.12) between Treatments A and B (7.41 versus 7.40, respectively) but was lower (P &lt; .001) at end of treatment during Treatment B than A (7.47 versus 7.51). HCO3 transfer from the dialysate to blood during A, B and C treatments were 140 ± 58, 97 ± 47 and 120 ± 47 mEq, respectively. HCO3 transfer trended lower (P = .09) during treatment B than A.

CONCLUSION
HD treatments with a dialysate [HCO3] of 35 mEq/L for only the first 2-h led to a reduction in HCO3 transfer to the patient and lower post-dialytic blood [HCO3] and pH. Lowering dialysate [HCO3] after 2-h of a 4-h HD treatment can reduce post-dialytic metabolic alkalosis. Further, long-term studies with such a strategy are needed to evaluate its effect on patient outcomes.
MO659: First Experience of Bamlanivimab for Covid-19 Positive Haemodialysis Patients: A Case-Control Study
Authors: Djuric Petar , Bogicevic Jovana , Pešić Snezana , Davidovic Zeljko , Naumovic Radomir 
Published: May 2022

Abstract

BACKGROUND AND AIMS
The previous study showed a higher prevalence of coronavirus (COVID-19) in end-stage renal disease (ESRD) patients than in the general population (3.1% versus 0.1%). The presence of COVID-19 infection significantly increased the mortality rate of patients on dialysis compared to non-COVID patients (20.2% versus 0.2%). To date, no clear guidelines exist for the management of COVID-19 in renal patients. Bamlanivimab is a potent neutralizing monoclonal antibody that blocks severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attachment and entry into human cells, which could potentially lead to therapeutic benefit. To our knowledge, this is the first study to use bamlanivimab in COVID-19+ haemodialysis (HD) patients with the aim to determine the effect of bamlanivimab on the mortality of these patients.

METHOD
We conducted a retrospective case-control study across a single HD centre of non-hospitalized HD patients, with documented positive SARS-CoV-2 testing. We analysed the period from October 1 to November 14 2021, in which COVID-19+ patients were dialyzed in our institution. Cases were defined as HD patients who received bamlanivimab and controls were patients who did not receive bamlanivimab. Descriptive statistics, including chi-squared and Mann–Whitney U test, were performed. We used multinomial logistic regression to find the independent relationship between bamlanivimab use, disease severity, coronary artery disease (CAD), heart failure and 1-month mortality risk.

RESULTS
Patients who received bamlanivimab frequently had the chronic obstructive pulmonary disease (COPD) than those in the control group. There were no significant differences between groups in any of the other parameters assessed (Table 1). Besides higher baseline ferritin levels in the control group, no other significant differences in biochemical markers were found between examined groups (Table 2). Over a 1-month follow-up, one patient (7.7%) died in the bamlinivimab group, while 8 patients (44.4%) died in the control group. Multinomial logistic regression revealed that no bamlanivimab treatment was given. CAD and disease severity increased the risks of mortality 39.1 times (P = 0.12), 81.7 times (P = 0.08) and 99.9 times (P = 0.04), respectively.

CONCLUSION
In COVID-19+ HD patients, bamlanivimab has been a safe and effective treatment method, lowering mortality although not statistically significant. We also discovered that having a more severe clinical presentation at baseline, as well as having a CAD, was related to a greater risk of mortality. Our findings imply that larger, more conclusive clinical studies of bamlanivimab in HD patients with COVID 19 should be conducted.
MO661: Elimination of Middle and Large Uraemic Toxins in Short Daily Home Haemodialysis with Low Dialysate Volume: A Randomized Crossover Clinical Trial
Authors: González Moya Mercedes , Molina Pablo , Molina Mariola D , García-Valdelvira María , Vizcaíno Belén , Montesa Marín María , Ventura Josep , Pérez-Zafra Erika , Calatayud Emma , Valero Alejandro , Beltrán Sandra , Estañ Nuria , Asuncion Sancho Calabuig Maria 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Portable haemodialysis (HD) systems with a low dialysate flow rate in a short frequent schedule have become an attractive option for patients on home HD (HHD). Although these systems have been demonstrated to be effective for removing low weight molecular uraemic toxins, there are few data on their removal ability of higher molecular weight toxins. This study assessed the uraemic toxin removal ability of the portable Physidia S3 Monitor in a short, frequent, 5 days/week, low-dialysate flux HHD versus 3 days/week, in centre online haemodiafiltration (OL-HDF).

METHOD
In an open, randomized, cross-over, single-centre, controlled, prospective study, 40 adult chronic HD patients were treated by a 2.5-h low flux dialysate HD session or a 4-h post-dilution OL-HDF. All other dialysis parameters including dialyzer (polysulfone high-flux dialyzer NS 1.8, Toray®) were kept constant in both the study arms. The weekly reduction rate (RR) and the weekly eliminated mass into dialysate (EM) of urea, creatinine, phosphate, β2-microglobulin, kappa (κFLC) and lambda (λFLC) free light chains and albumin, were intra-individually compared for the two dialysis types with linear mixed models.

RESULTS
There were no significant differences in the RR for urea, phosphate, κFLC and albumin, whereas the weekly RRs for creatinine and β2-microglobulin were significantly higher with the Physidia S3 system than those obtained with OL-HDF (Table). Only the λFLC RR was significantly higher with OL-HDF. Similar results were observed when weekly EMs were compared (data not shown).

CONCLUSION
This study demonstrates that treating patients with low flow dialysate HHD in a short frequent schedule with Physidia S3 system, instead of 3 days/week, in-centre OL-HDF, significantly increases the weekly elimination of β2-microglobulin, enabling an adequate clearance of small and large uraemic toxins.
MO663: No Translocation of Intact Intestinal Bacteria During Intermittent Dialysis Therapies
Authors: Rootjes Paul A , Budding Andries E , de Roij van Zuijdewijn Camiel , Bontkes Hetty J , Van Ittersum Frans J , Nubé Menso J , Wijngaarden Gertrude , Grooteman Muriel 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Accumulating evidence shows that online post-dilution haemodiafiltration (HDF), especially when a high convection volume is achieved, is associated with a lower mortality risk than haemodialysis (HD) [1]. The mechanism behind this effect, however, is unclear. In this respect, a superior intradialytic organ perfusion and hence, less intestinal tissue damage, permitting the transfer of bacteria from the gut to the blood, might play an important role. Therefore, we assessed whether differences exist in the intradialytic translocation of intact bacteria between four dialysis modalities.

METHOD
A randomized cross-over trial was performed (NCT03249532, ClinicalTrials.gov) in 11 prevalent dialysis patients, who were exposed to four dialysis strategies: HD with standard dialysate temperature (Td) 36.5°C and cool (Td 35.5°C) dialysate, and HDF with a high (≥23 L/1.73 m2/session) and low (15 L/1.73 m2/session) convection volume. Microbial DNA (mDNA), soluble CD14, high-sensitivity CRP and IL-6 receptor were measured during each modality, as secondary endpoints of this study. Quantitative assessment of mDNA was performed by 16S-23S interspace profiling after DNA isolation [2, 3]. In the current analysis, the quantitative difference in circulating mDNA between modalities was investigated. In addition, differences in the acute phase reaction (APR), as measured by soluble CD14, high-sensitivity CRP and IL-6 receptor and potential relations between mDNA and the APR were analysed.

RESULTS
DNA of intact bacteria could not be demonstrated in blood samples of the patients in any dialysis strategy. Yet, in all modalities a similar increase in IL-6 receptor, high-sensitivity CRP and soluble CD14 was observed (pre- versus post-dialysis: P-values &lt;.05) (Figures 1A-B).

CONCLUSION
i) The appearance of DNA from intact bacteria in the blood of dialysis patients could not be demonstrated, despite the use of a sensitive state-of-the-art technique, which is free from contamination by human DNA; ii) during all modalities a comparable and significant APR was observed; iii) hence, the intradialytic APR does not seem to result from translocated intact bacteria.
MO664: Assisted Peritoneal Dialysis (APD): Is it Only for the Old?
Authors: Haridian Sosa Barrios R. , Burguera Vion Víctor , Campillo Trapero Cristina , Viera Ramírez Elizabeth , Martin Irene , Mínguez Toral Irene , Fernandez Lucas Milagros , Rivera Maite 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Patients with end-stage kidney disease (ESKD) are becoming older and more comorbid. We define assisted peritoneal dialysis (aPD) as any PD treatment that needs the help of another person regardless of the age of the patient and the duration of such help. Our aim was to analyse our aPD experience.

METHOD

RESULTS

CONCLUSION
aPD should be considered not only in the elder or fragile, but also in cases of variable disability regardless of patient age. It does not imply a higher complication rate or a technique failure, and careful caregiver support should be provided to avoid exhaustion and PD abandonment.
MO667: Creating a New Cardiorenal Unit: 3-Year Study Results
Authors: Pérez Martínez Juan , Javier Centellas Pérez Francisco , Fuentes Manso Raquel , Gómez Pérez Alberto , Gallego Sánchez Gonzalo , Ortega Cerrato Agustin 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Cardiorenal syndrome is a clinical manifestation of the bidirectional interaction between the heart and kidney diseases, so creating specific units between cardiologists and nephrologists is necessary for better treatment of these patients.
In our hospital we have recently formed a workgroup for better organization of patients who need peritoneal dialysis (PD) and day-hospital assistant.
The aim of this study is to analyse the evolution of the patients in our PD program since the creation of a new cardiorenal unit in our center.

METHOD
This study includes patients beginning PD due to cardiorenal syndrome since the creation of our cardiorenal unit, between 15 June 2018 and 14 June 2021. We have registered the date of PD initiation and also the date of exclusion of the technique. Also we performed a pre–post observational study comparing the number of hospitalizations/emergency visits in the year before PD starts and its evolution for the next year. Statistical study was analysed with SPSS software, for a P-value &lt;0.05.

RESULTS
Twelve patients (9 men and 3 women) have been included in this study. The mean age was 66.50 years (range 50–82). PD survival was 34.43 months (range 7–70). The number of hospitalizations/emergency visits was 8.04 in the year before PD started, and 0.44 the next year (P &lt; 0.05). Nine of 12 patients had zero hospitalizations in the 12 months after initiating PD.

CONCLUSION
PD is an interesting treatment option for patients with cardiorenal diseases, which allows a significant reduction in hospitalization and decompensation rates. Creating new cardiorenal units is a good option for the integral management of these patients.
MO669: Predictive Parameters of Automated PD Cycler Software for Diagnosis of Catheter Dysfunction
Authors: Arianna Oviedo Flores Krystell , Kaltenegger Lukas , Eibensteiner Fabian , Unterwurzacher Markus , Kratochwill Klaus , Aufricht Christoph , König Franz , Vychytil Andreas 
Published: May 2022

Abstract

BACKGROUND AND AIMS
An adequately functioning catheter is of vital importance for successful long-term treatment and technique survival to peritoneal dialysis (PD) patients. According to the 2021 International Society of Peritoneal Dialysis guidelines on membrane function, catheter drainage problems should be suspected first in patients with low ultrafiltration (UF) capacity. Catheter dysfunction and the consequent decrease in UF are frequent complications in PD patients associated with significant negative clinical outcomes.

METHOD
We introduce the use of a combination of parameters obtained from daily measurements of the cycler software PD Link (Baxter) for predicting catheter dysfunction in automated peritoneal dialysis (APD) patients. Out of 117 APD patients treated at the Medical University of Vienna from 2015 to 2021, we identified all patients with verified catheter malposition and dysfunction (n = 14, cases) and compared them to controls without clinical evidence of mechanical problems and a recent X-ray confirming position of the PD catheter tip in the recto-vesical/recto-uterine space (n = 19). We retrieved cycler data for 7 days each and tested parameters predictive capability of catheter dysfunction.

RESULTS
Total number of alarms/week &gt;7 as single predictive parameter of catheter dislocation identified 85.7% (sensitivity) of patients with dislocated catheter and 31.6% (1—specificity) of control patients. A combination of two out of three parameters (number of alarms/week &gt;7, drain time &gt;22 min, UF of last fill &lt;150 mL) identified the same proportion of patients with catheter dislocation, but was more accurate in identifying controls (21% false positive).

CONCLUSION
We confirmed our clinical impression that number of alarms, total drain time at the end of cycler session and UF of last fill are good predictors for mechanical drainage problems. In contrast to yearly peritoneal equilibration test measurements, these data provide valuable information for clinical management of PD patients on a daily base and will be easily available in new APD cyclers with devices connected to remote monitoring platforms.